Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efalizumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| efalizumab | DRUG | - |
Inclusion Criteria: * Signed informed consent * Plaque psoriasis covering \>=10% of total BSA * Plaque psoriasis diagnosed for at least 6 months * In the opinion of the investigator, a candidate for systemic therapy for psoriasis * 18-75 years old * Body weight \<=125 kg * For women of childbearing...
Efalizumab is an investigational drug being studied for the treatment of psoriasis, a dermatological condition. It is being evaluated in adults with plaque psoriasis, including those who are receiving concomitant antipsoriatic therapies. The drug is in Phase 3 clinical development and is not yet approved.
Efalizumab is being developed by Roche Holding AG, a pharmaceutical company traded on the OTC market under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with psoriasis.
Efalizumab is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of psoriasis in adults, with one completed Phase 3 trial involving 1,200 participants.
Efalizumab has one completed Phase 3 clinical trial registered under NCT00338143, titled 'A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies.' The trial enrolled 1,200 adults aged 18 years and older with psoriasis.
Efalizumab is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of psoriasis. The drug has completed one clinical trial, but it remains under investigation and has not received regulatory approval.